Company Profile

Aderis Pharmaceuticals Inc (AKA: Discovery Therapeutics Inc)
Profile last edited on: 5/29/21      CAGE:       UEI:

Business Identifier: Small molecule drugs to treat central nervous system, cardiovascular and renal disorders
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

85 Main Street
Hopkinton, MA 01748
   (508) 497-2300
Location: Multiple
Congr. District: 04
County: Middlesex

Public Profile

In July 2005, Aderis Pharmaceuticals, Inc. was acquired by Schwarz Pharma Ltd. Formerly known as Discovery Therapeutics, Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of receptor subtype-selective compounds for the treatment of cardio-renal diseases. The firm's product pipeline inluded adenosine agonists and antagonists for the diagnosis and treatment of cardiovascular disease and FLAP antagonists for the treatment of chronic kidney disease. Primarily focused on CNS, cardiovascular and renal therapeutics, the firmorganized around developing small molecule drug candidates that act selectively to either inhibit or increase the activity of certain proteins, such as receptors and enzymes that regulate important physiologic functions. That the selectivity of drug candidates offered the potential for safe and effective therapies with minimal side effects with small molecule drug candidates offering dosing flexibility for optimal patient convenience.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1996 1 NIH $100,000
Project Title: Adenosine A 2a--Selective Agonists For Inflammation
1996 1 NIH $100,000
Project Title: Adenosine Antagonist For Cardiopulmonary Resuscitation
1995 1 NIH $100,000
Project Title: A2a--Adenosine Agonist for Cardiovascular Imaging

Key People / Management

  Peter G Savas -- former President

  Sharon Correia -- Director, Corporate Communications

  Noel J Cusack -- former Chief Scientific Oficer and Co-Founder

  Pauline Martin

  Donald A McAfee -- Chief Technical Officer

  Gevork Minaskanian -- VP, Chemistry

  James V Peck -- VP, Research Operations

  Kenneth L Rice -- VP, CFO & CCO

  William Wheeler -- VP & CMO

Company News

There are no news available.